We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+16.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$276M
AUM Growth
+$59.5M
Cap. Flow
+$34.9M
Cap. Flow %
12.66%
Top 10 Hldgs %
29.49%
Holding
157
New
25
Increased
65
Reduced
12
Closed
31

Top Buys

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$7.96M
2
HES
Hess
HES
+$4.24M
3
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.06M
4
SP
SP Plus Corporation
SP
+$3.96M
5
PATH icon
UiPath
PATH
+$2.41M

Top Sells

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$5.76M
2
VMW
VMware, Inc
VMW
+$5.59M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.04M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.03M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 45.71%
2 Technology 11.75%
3 Consumer Discretionary 6.51%
4 Industrials 5.31%
5 Consumer Staples 4.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.69B
$31.7M 11.49%
1,436,136
– –
SYRE icon
2
Spyre Therapeutics
SYRE
$8.5B
$12.4M 4.51%
+577,616
New +$7.96M
MSFT icon
3
Microsoft
MSFT
$2.9T
$5.44M 1.97%
14,458
+4,500
+45% +$1.6M
IMVT icon
4
Immunovant
IMVT
$7.93B
$5.11M 1.85%
121,287
+14,379
+13% +$529K
AXSM icon
5
Axsome Therapeutics
AXSM
$11.7B
$4.96M 1.8%
62,263
+5,299
+9% +$354K
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.43B
$4.51M 1.64%
126,845
– –
ACI icon
7
Albertsons Companies
ACI
$5.85B
$4.34M 1.58%
188,753
– –
VRDN icon
8
Viridian Therapeutics
VRDN
$2.2B
$4.32M 1.57%
198,484
+93,728
+89% +$1.48M
IMGN
9
DELISTED
Immunogen Inc
IMGN
$4.29M 1.56%
144,772
– –
SPLK
10
DELISTED
Splunk Inc
SPLK
$4.2M 1.53%
27,600
– –
HES
11
DELISTED
Hess
HES
$4.17M 1.51%
+28,900
New +$4.24M
CERE
12
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.12M 1.5%
97,200
+72,313
+291% +$2.08M
SOVO
13
DELISTED
Sovos Brands, Inc. Common Stock
SOVO
$4.07M 1.48%
+184,600
New +$4.06M
SP
14
DELISTED
SP Plus Corporation
SP
$4.04M 1.47%
+78,900
New +$3.96M
ACLX
15
DELISTED
Arcellx
ACLX
$4.01M 1.45%
72,230
-5,798
-7% -$262K
NUVL
16
DELISTED
Nuvalent
NUVL
$3.98M 1.44%
54,083
– –
CRM icon
17
Salesforce
CRM
$154B
$3.94M 1.43%
14,979
+4,500
+43% +$1.02M
INSM icon
18
Insmed
INSM
$22.4B
$3.93M 1.43%
126,780
+46,780
+58% +$1.21M
CPRI icon
19
Capri Holdings
CPRI
$1.82B
$3.9M 1.42%
77,700
– –
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
$3.79M 1.37%
160,334
-19,971
-11% -$356K
AMED
21
DELISTED
Amedisys
AMED
$3.73M 1.35%
39,250
– –
MRUS
22
DELISTED
Merus
MRUS
$3.67M 1.33%
133,572
+10,941
+9% +$255K
MLTX icon
23
MoonLake Immunotherapeutics
MLTX
$1.56B
$3.61M 1.31%
59,769
– –
OLMA icon
24
Olema Pharmaceuticals
OLMA
$977M
$3.48M 1.26%
247,880
– –
V icon
25
Visa
V
$677B
$3.21M 1.16%
12,327
+3,600
+41% +$887K
1
2 3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

HighVista Strategies's Q4 2023 Portfolio in Review

As of Q4 2023, HighVista Strategies held 157 positions worth $276M, up 28% from $216M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies deployed $34.9M of net new capital in Q4 2023, opening 25 new positions and adding to 65 existing holdings. Its largest new stake was Spyre Therapeutics: 577,616 shares worth $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Micron Technology, an estimated $780K trimmed.

  • HighVista Strategies's largest Q4 2023 buy was Spyre Therapeutics: 577,616 shares worth $12.4M.
  • HighVista Strategies added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023, an estimated $2.08M increase.
  • HighVista Strategies's biggest Q4 2023 reduction was Micron Technology, cutting an estimated $780K.
  • HighVista Strategies fully exited Activision Blizzard in Q4 2023, selling an estimated $5.76M.
  • HighVista Strategies's ten largest holdings make up 29% of its $276M portfolio in Q4 2023.
  • HighVista Strategies opened 25 new positions and closed 31 in Q4 2023.
  • HighVista Strategies's portfolio value rose 28% quarter-over-quarter to $276M.

Based on HighVista Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.